Regulatory and Ethical Context The FDA has approved recombinant human IGF-1 only as mecasermin (Increlex) for the narrow indication of severe primary IGF-1 deficiency or GH-gene deletion with neutralising antibodies to GH, in children [15]
Clinical trials show participants lose an average of 15-22% of body weight over 68 weeks, yet individual timelines vary significantly based on genetics, lifestyle, and baseline health status
Addressing biological factors such as hormones, metabolism, and appetite regulation gives patients a real chance at lasting results
The gut microbiotas influence extends to the modulation of autoimmune responses through molecular mimicry
Soboba Weight Loss meets those needs by providing B Complex shots, B12 injections, HCG Diet support, Lipo B injections, Ozempic, and Mounjaro through a physician-guided model with locations in nearby Orange County